VDJ
VDJ is an antibody affinity enhancement platform that simulates the maturation mechanism of human antibodies and is specialized in autoimmune diseases. Their products include IL-6R antibodies and CTLA-4-Ig. They serve markets.
VDJ
Social Links:
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2011-07-20
Address:
Haidian, Beijing, China
Country:
China
Website Url:
http://www.vdjbio.com
Total Employee:
11+
Status:
Active
Contact:
010-62987077
Total Funding:
56 M CNY
Technology used in webpage:
Alibaba Chinese Server Location Baidu Share
Similar Organizations
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Hua Medicine
Hua Medicine is a clinical-stage, innovative drug development company in China.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Primoris Therapeutics
Primoris Therapeutics is a medical research and development center.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Employees Featured
Founder
Investors List
Liyuan Venture Capital
Liyuan Venture Capital investment in Series C - VDJ
Huadian Investment
Huadian Investment investment in Series C - VDJ
Beijing Venture Capital
Beijing Venture Capital investment in Series C - VDJ
Yiyuan Investment
Yiyuan Investment investment in Series C - VDJ
Lotus Lake Ventures
Lotus Lake Ventures investment in Series C - VDJ
Hongcheng Capital
Hongcheng Capital investment in Series C - VDJ
Li Zaifu
Li Zaifu investment in Series C - VDJ
Beijing Youhe Dingxin Equity Investment Management
Beijing Youhe Dingxin Equity Investment Management investment in Series C - VDJ
Beijing Hankang Chuangye Touzi
Beijing Hankang Chuangye Touzi investment in Series B - VDJ
Beijing Yinglida Biological Technology
Beijing Yinglida Biological Technology investment in Series A - VDJ
Official Site Inspections
http://www.vdjbio.com Semrush global rank: 12.93 M Semrush visits lastest month: 78
Unable to get host informations!!!
More informations about "VDJ"
北京伟德杰生物科技有限公司
北京伟德杰生物科技有限公司 (简称：伟德杰生物）国家高新技术企业、北京市专精特新中小企业。 专注于自身免疫疾病领域同类的创新抗体药物开发，凭借其自有的模拟人体抗体成熟机理的抗体亲和力提高与优化平台，大分子药物小试、中 …See details»
VDJ - Crunchbase Company Profile & Funding
VDJ is an antibody affinity enhancement platform that simulates the maturation mechanism of human antibodies and is specialized in autoimmune diseases. Their products include IL-6R …See details»
Beijing Weidejie Biotechnology Co., Ltd. - Drug pipelines, Patents ...
Beijing VDJ BioCo., Ltd. was established in July 2011 and is committed to the independent research and development of innovative monoclonal antibody drugs.See details»
北京伟德杰生物科技有限公司-北京伟德杰 ... - vdjbio.com
北京伟德杰生物科技有限公司 (简称：伟德杰生物）国家高新技术企业、北京市专精特新中小企业。 专注于自身免疫疾病领域创新抗体药物开发，凭借其自有的模拟人体抗体成熟机理的抗体 …See details»
VDJ Biotechnology - PitchBook
Description. Developer of monoclonal antibody (moAb) and fusion protein drugs designed to treat autoimmune diseases.See details»
Beijing Weidejie Biotechnology Co., Ltd.
北京伟德杰生物科技有限公司. NCT05957107 / Completed 临床2期. Randomized, Double-blind, Placebo, Positive-controlled Phase II Trial of VDJ001 in Patients With Moderate-to-severe …See details»
伟德杰-北京伟德杰生物科技有限公司-企业详情-InvestGO数据库-By…
北京伟德杰生物科技有限公司（Beijing VDJBio Co., LTD.）成立于2011年7月，致力于创新单克隆抗体药物的自主研发，重点是研发下一代药效高、安全性高、生产成本低的生物制品。 公司 …See details»
VDJBio - Products, Competitors, Financials, Employees, …
VDJBio is a biotechnology company focused on the development of pharmaceuticals for oncology and autoimmune diseases. The company's main offerings include research and development …See details»
Beijing VDJBio Co., Ltd. Asset Profile - Preqin
Based in Beijing, China and established in 2011, Beijing VDJBio Co., Ltd. is a biotechnology company that focuses on the research and development of innovative antibody drugs for …See details»
VDJBio completes Series C financing and promotes clinical …
Jun 6, 2023 · VDJBIO-VDJ001 is a recombinant humanized monoclonal antibody injection that targets interleukin-6 (IL-6) receptors. Currently, the company’s leading product, VDJ001, has …See details»
VDJ-001 - Drug Targets, Indications, Patents - Synapse - Patsnap
This is a multicenter, randomized, double-blind, placebo and tocilizumab controlled phase II trial in RA patients to evaluate the initial efficacy, safety, pharmacokinetic, pharmacodynamic …See details»
研发中心-北京伟德杰生物科技有限公司 - vdjbio.com
公司利用自主研发技术平台，20+研发管线覆盖自身免疫疾病主流靶点，多个项目处在不同的研发阶段。 在研产品都属于国家一类新药，所涉及的治疗领域具有百亿美元的市场。 研发中心独 …See details»
VDJ010 - Drug Targets, Indications, Patents - Synapse - Patsnap
VDJ010, Initially developed by Beijing Weidejie Biotechnology Co., Ltd., Now, its global highest R&D status is Phase 1, Therapeutic Areas: Immune System Diseases,Digestive System …See details»
Scientific Abstracts - Annals of the Rheumatic Diseases
Objectives: VDJ-001 is a novel humanized IgG1 monoclonal antibody designed to enhance the therapeutic index of Tocilizumab.See details»
我们的优势-北京伟德杰生物科技有限公司 - vdjbio.com
专注于自身免疫疾病领域创新抗体药物开发，凭借其自有的模拟人体抗体成熟机理的抗体亲和力提高与优化平台，大分子药物小试、中试、产业化生产平台，开发了一系列治疗自免疾病的抗 …See details»
伟德杰生物宣布VDJ-001在类风湿关节炎Ⅱ期临床研究中取得积极 …
Aug 7, 2023 · 北京伟德杰生物科技有限公司 宣布 VDJ-001注射液 在 类风湿关节炎的 Ⅱ 期临床 研究中取得 可 喜的 里程碑成果。 该项临床研究 结果显示， VDJ-001在181 例 对 MTX响应不佳 …See details»
企业文化-北京伟德杰生物科技有限公司 - vdjbio.com
北京伟德杰生物科技有限公司. 010-62987077 010-62987077 北京市海淀区永腾北路9号院海星医药健康创新园a区8号楼See details»
Tocilizumab biobetter - Beijing Weidejie Biotechnology
Tocilizumab biobetter (VDJ 001) is being developed by Beijing Weidejie Biotechnology (VDJBio) for the treatment of castleman's disease [giant lymph node.See details»
tocilizumab biobetter (VDJ001) / VDJBio - LARVOL
VDJ-001 is safe and effective in patients with rheumatoid arthritis. Its higher affinity and higher biological activity seem to be associated with the tendency of higher efficacy. The highly …See details»
新闻中心-北京伟德杰生物科技有限公司 - vdjbio.com
2024年3月19日，北京伟德杰生物科技有限公司（简称：伟德杰生物）自主开发的I类新药长效Treg激活剂（VDJ010）临床试验申请，获得国家药品监督管理局药品审评中心（CDE）的批 …See details»